AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Elanco Animal Health (ELAN) Soars 1.34% on Upgrade
Generated by AI AgentAinvest Movers Radar
Friday, Jul 18, 2025 6:49 pm ET1min read
Aime SummaryElanco Animal Health (ELAN) shares rose to their highest level since September 2024 today, with an intraday gain of 1.34%.
The strategy of buying ELAN shares after they reached a recent high and selling them one week later delivered moderate returns but underperformed the market. The strategy’s CAGR was 10.08%, trailing the benchmark by 30.71%. With a maximum drawdown of 0.00% and a Sharpe ratio of 0.24, the strategy had minimal risk but offered conservative returns, making it suitable for investors seeking stability.Leerink Partners has upgraded Elanco Animal Health's rating from "hold" to "strong-buy," citing strong early interest in its new U.S. pet health product, Credelio Quattro. The price target was raised from $14.50 to $18.00.
On July 17, 2025, Elanco received a significant upgrade from Leerink Partners, and the stock was upgraded from Market Perform to Outperform with a price target increase to $18.
Elanco's stock price has recently crossed above the average analyst 12-month target price of $14.94, prompting analysts to consider reassessing their target prices due to potential positive business developments.
Ainvest Movers Radar
Knowing stock market today at a glance
Latest Articles
Sharp Downturn in LENZ.O: What's Behind the 29% Intraday Drop?
Dec.12 2025
Quanex (NX.N) Spikes 9% on Inverse Head-and-Death Cross Amid Divergent Peer Moves
Dec.12 2025
Why Did BTQ.O Drop 6.4% Without Major News?
Dec.12 2025
Gogo (GOGO.O) Sharp Intraday Drop: Technical, Order Flow, and Peer Analysis
Dec.12 2025
Unpacking the Sudden 5.1% Rally in Churchill X (CCCX.O): A Deep Dive
Dec.12 2025
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet